Details

Autor(en) / Beteiligte

• Horton, Amanda L
• Lai, Yinglei
• Rouse, Dwight J
• Spong, Catherine Y
• Leveno, Kenneth J
• Varner, Michael W
• Mercer, Brian M
• Iams, Jay D
• Wapner, Ronald J
• Sorokin, Yoram
• Thorp, John M
• Ramin, Susan M
• Malone, Fergal D
• O'Sullivan, Mary J
• Hankins, Gary D V
• Caritis, Steve N

Titel

Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes

Ist Teil von

• American journal of perinatology, 2015-03, Vol.32 (4), p.387-392

Ort / Verlag

United States

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• This study aims to evaluate whether magnesium sulfate administration for neuroprotection prolongs latency in women with preterm premature rupture of membranes (PPROM) between 24 and 31(6/7) weeks' gestation. This is a secondary analysis of a randomized controlled trial of magnesium sulfate for prevention of cerebral palsy. Gravid women with a singleton pregnancy between 24 and 31(6/7) weeks' gestation with PPROM without evidence of labor were randomized to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour up to 12 hours, or placebo. Maternal outcomes for this analysis were delivery in less than 48 hours and in less than 7 days from randomization. Neonatal outcomes included a composite of respiratory distress syndrome, interventricular hemorrhage grades 3 or 4, periventricular leukomalacia, sepsis, necrotizing enterocolitis, retinopathy of prematurity, or death. A total of 1,259 women were included. The rate of delivery < 48 hours was not different in the magnesium sulfate and the placebo groups (22.2 and 20.7%, p = 0.51). Delivery < 7 days was similar between groups (55.4 and 51.4%, p = 0.16). Median latency was also similar between groups (median [interquartile range], 6.0 days [range, 2.4-13.8 days] and 6.6 days [range, 2.4-15.1 days], p = 0.29). Composite neonatal outcomes did not differ between groups. Magnesium sulfate administration given for neuroprotection in women with a singleton gestation with PPROM and without labor before 32 weeks does not impact latency.